Vanguard reports 5.19% stake in Anika Therapeutics

Anika Therapeutics Inc ownership filing: Vanguard Capital Management reports beneficial ownership of 695,697 shares of Common Stock, representing 5.19% of the class.

Rhea-AI Filing Summary

Anika Therapeutics Inc ownership filing: Vanguard Capital Management reports beneficial ownership of 695,697 shares of Common Stock, representing 5.19% of the class. The filing shows sole voting power of 89,920 shares and sole dispositive power for 695,697 shares.

The filing is submitted on behalf of Vanguard Capital Management and affiliated business divisions; the signature is by Ashley Grim, Head of Global Fund Administration.

Insights

Institutional Ownership Analyst

Vanguard holds a >5% passive stake in Anika Therapeutics.

Vanguard Capital Management reports beneficial ownership of 695,697 shares (5.19%), a threshold that requires public disclosure under Schedule 13G reporting rules. The filing attributes voting and dispositive powers across Vanguard entities.

Holding this size can appear on investor ownership screens; subsequent 13G/A or 13D filings would indicate changes in intentions or activism. Future filings may update percentages if positions change.

Regulatory Compliance Specialist

Filing follows passive investor disclosure guidance.

The statement cites SEC Release No. 34-39538 and lists affiliated Vanguard entities that exercise dispositive power, consistent with aggregated reporting for investment managers. The signature block shows an authorized officer certified the report.

This Schedule 13G signals passive reporting status under the Exchange Act; any shift toward active influence would typically trigger a different reporting form.

Key Figures

Beneficial ownership: 695,697 shares Percent of class: 5.19% Sole voting power: 89,920 shares +2 more

5 metrics

Beneficial ownership 695,697 shares reported on Schedule 13G

Percent of class 5.19% percentage of common stock reported

Sole voting power 89,920 shares shares with sole voting power

Sole dispositive power 695,697 shares shares with sole power to dispose

Signature date 04/29/2026 filing signed by Ashley Grim

Key Terms

Schedule 13G, Beneficial ownership, Dispositive power, Sole voting power

4 terms

Schedule 13G regulatory

"Vanguard Capital Management reports beneficial ownership on Schedule 13G"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

Beneficial ownership financial

"Amount beneficially owned: 695697 (b) Percent of class: 5.19%"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

Dispositive power regulatory

"Sole power to dispose or to direct the disposition of: 695697"

Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.

Sole voting power regulatory

"Sole power to vote or to direct the vote: 89920"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does Vanguard Capital Management report in ANIK?

Vanguard reports beneficial ownership of 695,697 shares, representing 5.19% of Anika Therapeutics' common stock, as stated in the filing. The filing aggregates holdings across Vanguard affiliates that exercise dispositive power.

Who filed the Schedule 13G for ANIK on behalf of Vanguard?

The filing was made by Vanguard Capital Management and affiliated divisions; it is signed by Ashley Grim, Head of Global Fund Administration. The filing lists Vanguard offices in Malvern, PA and cites affiliated entities.

What voting and dispositive powers does Vanguard report for ANIK shares?

Vanguard reports sole voting power over 89,920 shares and sole dispositive power over 695,697 shares. No shared voting or dispositive powers are reported in this filing.

Does the Schedule 13G indicate Vanguard is an activist investor in ANIK?

No. The filing follows Schedule 13G aggregation language and cites passive reporting guidance; it does not state activist intent. A change in intent would typically require a different filing type.

When was the Schedule 13G for ANIK signed?

The signature block shows the report was signed by Ashley Grim on 04/29/2026, certifying the information about holdings and powers exercised by Vanguard and its affiliates.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/29/2026 - 04:35 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Anika Therapeutics Inc

(Name of Issuer)

Common Stock

(Title of Class of Securities)

035255108

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 035255108

1

Names of Reporting Persons

Vanguard Capital Management

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

PENNSYLVANIA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 89,920.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 695,697.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

695,697.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.19 %

12

Type of Reporting Person (See Instructions)

IA

Comment for Type of Reporting Person: In accordance with SEC Release No. 34-39538 (January 12, 1998), this Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by Vanguard Capital Management LLC and the following affiliates of Vanguard Capital Management LLC or business divisions of such affiliates: Vanguard Asset Management Limited, Vanguard Fiduciary Trust Company, Vanguard Global Advisers, LLC and Vanguard Investments Australia Ltd. This Schedule 13G includes securities held by Vanguard funds, or sleeves thereof, over which Vanguard Capital Management LLC exercises dispositive power, in addition to securities held by clients over which the affiliates or business divisions of such affiliates indicated above exercise dispositive and/or voting power. This Schedule 13G does not include securities, if any, beneficially owned by other subsidiaries or affiliates of Vanguard Capital Management LLC, or business divisions of such subsidiaries, whose ownership of securities is disaggregated from that of the reporting business unit in accordance with such release.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Anika Therapeutics Inc
(b)	Address of issuer's principal executive offices: 32 Wiggins Avenue, Bedford, MA, 01730
Item 2.
(a)	Name of person filing: Vanguard Capital Management
(b)	Address or principal business office or, if none, residence: 100 Vanguard Blvd,, Malvern, PA, 19355
(c)	Citizenship: PA
(d)	Title of class of securities: Common Stock
(e)	CUSIP Number(s): 035255108
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 695697
(b)	Percent of class: 5.19 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 89920
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 695697
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. Vanguard Capital Management, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.No one other person's interest in the securities reported herein is more than 5%.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Vanguard Capital Management

Signature:	Ashley Grim
Name/Title:	Head of Global Fund Administration
Date:	04/29/2026